How to Decide, According to Neuroscience
Understanding how our brains weigh these decisions can help us bridge what feels good now with what truly matters. Recalibrating our decision-making process can help. That means making time to identify our bigger goals and thinking through clear and specific steps toward them. Then we can find ways to make small choices feel rewarding in both the near and the long term. Seeking out social rewards, reframing our choices and making small changes to how we consider each decision can help. This can make it easier to take action — even when challenges feel overwhelming.
Humans weigh choices in a brain network called the valuation system. It's where we identify the options we're choosing between, calculate the likely reward for each and make a choice. Close-to-home rewards ignite the system that pushes us to act. But when the rewards are distant or vague — such as influencing a sweeping government policy or making a major life change — the brain struggles to see the payoff, and motivation falters. That's why doughnuts can win out over our health goals and why we might binge-watch a show instead of going to a town meeting, even if we'd say that the latter actions are more compatible with who we want to be.
In brain scans, neuroscientists like me can see these processes unfold. Rewards that are far in the future, situations that are geographically far removed or events happening to someone else are all represented in similar ways; future you is akin to an acquaintance. The less vividly we imagine a reward, the less weight it gets in our value calculations. But when we try to motivate ourselves, we often focus on long-term benefits rather than nearer-term rewards. We're working against our brains when we try to motivate ourselves this way.
This year, I found myself in a situation that tested my ability to align how I was spending my energy day to day with things I care about deeply. The Trump administration cut billions of dollars in science, health and defense research investments to universities, which directly affects my lab at the University of Pennsylvania. This was part of a larger effort to cut health and science funding that will result in enormous economic pain, leave patients without care and make it harder to develop treatments for diseases like cancer, heart disease, dementia and depression.
I've lost loved ones to these diseases. I know the people whose jobs are at stake. And I know the cost of halting a clinical trial midway through. Despite understanding the stakes of these cuts, when the news first arrived about Penn, I felt paralyzed. I was unable to see how anything I could possibly do would help the situation. I'd lay in bed, doomscrolling — stress, after all, changes how the valuation system functions.
Want all of The Times? Subscribe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Bush, Obama and Bono bid farewell to USAID as researchers warn agency's closure means 14m extra deaths
Staff at the U.S. Agency for International Development (USAID) marked their final day on the job on Monday with tributes from two former presidents and a rock legend as new research revealed the stark reality of life without their help. George W Bush, Barack Obama and U2 frontman Bono expressed their thanks to departing employees from the international aid agency in heartfelt video messages as their offices were shuttered under President Donald Trump's 'America First' agenda. Secretary of State Marco Rubio announced in March that 83 percent of USAID's programs would be cut because they did not serve 'the core national interests of the United States,' with the remainder of the agency being folded into his department. But fresh doubt was cast on the wisdom behind that decision by findings published in The Lancet medical journal on the same day staff were saying goodbye, which indicated that 14 million more people will die over the next five years without the humanitarian support USAID once provided. An international team of researchers found the agency's global outreach efforts had prevented 92 million deaths between 2000 and 2021 across 133 countries, saving the lives of 25 million HIV/Aids sufferers, 11 million people with diarrheal diseases, 8 million with malaria and nearly 5 million with tuberculosis. Of the 14 million extra deaths, 4.5 million will be accounted for by children under five, they concluded. Davide Rasella of the Barcelona Institute for Global Health, one of the report's co-authors, called the findings 'striking' and said the likely impact on low and middle-income countries will be 'comparable in scale to a global pandemic or a major armed conflict.' He added that the cuts to USAID 'risk abruptly halting – and even reversing – two decades of progress in health among vulnerable populations.' The agency, founded in 1961, managed a budget of $35bn last year, according to the Congressional Research Service, and was involved in everything from running health clinics and building schools to more mundane but vital tasks like distributing nutrition pouches, mosquito nets and chlorine tablets. 'You've shown the great strength of America through your work, and that is our good heart,' Bush told the outgoing workers on Monday, according to The New York Times, also thanking them for enacting his signature Emergency Plan for Aids Relief. 'Is it in our interest that 25 million people who would have died now live? I think it is,' he said. 'On behalf of a grateful nation, thank you for your hard work, and God bless you.' Obama, in turn, attacked the decision to close USAID as 'a colossal mistake' and lamented: 'Ending your presence and your programs out in the world hurts the most vulnerable, and it hurts the United States. 'To many people around the world, USAID is the United States.' Bono, well known for his advocacy for developing nations, chose to deliver his message in rhyme and said: 'They called you crooks – when you were the best of us, there for the rest of us. And don't think any less of us, when politics makes a mess of us. 'It's not left-wing rhetoric to feed the hungry, heal the sick. If this isn't murder, I don't know what is.' The Lancet's forecast appeared to bear out his assessment and the research it published is by no means the only study to have anticipated such a bleak outcome from USAID's closure. A Boston University model, for instance, has put the human cost of its demise in even more shocking terms: 88 deaths per hour. Amira Albert Roess, a professor of global health and epidemiology at George Mason University, told NBC News it was the speed of the Trump administration's decision that is so dangerous. 'For better or for worse, some of the USAID-funded clinics in some areas, they were the main source of care,' she said. 'If you wanted to reduce USAID funding, it could have been done in a more gradual manner, instead of this sudden – and really, in a lot of places, overnight – shuttering of clinics.' Roess said she was particularly concerned by the abrupt closure of HIV clinics and warned: 'If you miss a dose or multiple doses, as was the case with lots of individuals, that's creating a situation where the individual can start to deteriorate fairly rapidly.' In May, Microsoft co-founder Bill Gates announced he would be bringing forward the charitable donation of $200bn from his personal fortune in order to help meet the shortfall and continue the fight against deadly diseases around the world. In doing so, Gates derided his fellow tech boss Elon Musk for his part in the cuts as the then-leader of Trump's Department of Government Efficiency (DOGE).
Washington Post
37 minutes ago
- Washington Post
Obesity drug prices are dropping, but getting a steady supply remains a challenge
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without insurance — out of reach for many patients. And even for people with insurance, coverage remains uneven. 'The medications should be available, the question is at what price and can people sustain that,' said Matt Maciejewski, a Duke University professor who studies obesity treatment coverage.
Yahoo
an hour ago
- Yahoo
Obesity drug prices are dropping, but getting a steady supply remains a challenge
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without insurance — out of reach for many patients. And even for people with insurance, coverage remains uneven. 'The medications should be available, the question is at what price and can people sustain that,' said Matt Maciejewski, a Duke University professor who studies obesity treatment coverage. Doctors say the situation forces them to get creative in treating patients, but there's hope that prices may fall more in the future. The drugs are still in high demand Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity. Zepbound brought in $2.3 billion in U.S. sales during this year's first quarter, making it one of drugmaker Eli Lilly's best sellers. Novo Nordisk says Wegovy has about 200,000 weekly prescriptions in the U.S., where it brought in nearly $1.9 billion in first-quarter sales. Insurance coverage is increasing — for some The benefits consultant Mercer says more businesses with 500 or more employees are adding coverage of the injected drugs for their workers and family members. And Novo says 85% of its patients who have coverage in the U.S. pay $25 or less per month. Plus some patients with diabetes can get coverage of the GLP-1 drugs Ozempic and Mounjaro from Novo and Lilly that are approved to treat that condition. But most state and federally funded Medicaid programs don't cover the drugs for obesity and neither does Medicare, the federal program mainly for people age 65 and older. Even the plans that cover the drugs often pay only a portion of the bill, exposing patients to hundreds of dollars in monthly costs, said Dr. Beverly Tchang. Drugmakers offer help with these out-of-pocket costs, but that assistance can be limited. 'Coverage is not the same as access,' said Tchang, a New York-based doctor who serves as a paid advisor to both Novo and Lilly. But coverage remains inconsistent Bill-payers like employers are nervous about drugs that might be used by a lot of people indefinitely. Some big employers have dropped coverage of the drugs due to the expense. Pharmacy benefit managers, or PBMs, also are starting to pick one brand over the other as they negotiate deals with the drugmakers. One of the nation's largest PBMs, run by CVS Health, dropped Zepbound from its national formulary, or list of covered drugs, on July 1 in favor of Wegovy. That forced Tchang to figure out another treatment plan for several patients, many of whom took Zepbound because it made them less nauseous. Dr. Courtney Younglove's office sends prospective patients a video link showing them how to check their insurer's website for coverage of the drugs before they visit. 'Then some of them just cancel their appointment because they don't have coverage,' the Overland Park, Kansas, doctor said. Cheaper compounded drugs are still being sold Compounding pharmacies and other entities were allowed to make off-brand, cheaper copies of Wegovy and Zepbound when there was a shortage of the drugs. But the U.S. Food and Drug Administration determined earlier this year that the shortage had ended. That should have ended the compounded versions, but there is an exception: Some compounding is permitted when a drug is personalized for the patient. The health care company Hims & Hers Health offers compounded doses of semaglutide, the drug behind Wegovy, that adjust dose levels to help patients manage side effects. Hims says these plans start at $165 a month for 12 months, with customers paying in full upfront. It's a contentious issue. Eli Lilly has sued pharmacies and telehealth companies trying to stop them from selling compounded versions of its products. Novo recently ended a short-lived partnership with Hims to sell Wegovy because the telehealth company continued compounding. Novo says the compounded versions of its drug put patient safety at risk because ingredients are made by foreign suppliers not monitored by US regulators. Hims says it checks all ingredients to make sure they meet U.S. quality and safety standards. It also uses a third-party lab to verify that a drug's strength is accurately labeled. Prices have dropped Both drugmakers are selling most of their doses for around $500 a month to people without insurance, a few hundred dollars less than some initial prices. Even so, that expense would eat up about 14% of the average annual per person income in the U.S., which is around $43,000. There are some factors that may suppress prices over time. Both companies are developing pill versions of their treatments. Those could hit the market in the next year or so, which might drive down prices for the older, injectable doses. Younglove said some of her patients save as much as 15% by getting their doses shipped from a pharmacy in Canada. They used to get them from an Israeli pharmacy until the Canadians dropped their prices. She says competition like this, plus the introduction of pill versions, will pressure U.S. prices. 'I think price wars are going to drive it down,' she said. 'I think we are in the early stages. I have hope.' ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group. The AP is solely responsible for all content. Tom Murphy, The Associated Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
